Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study of Zelavespib (PU-H71) in Subjects With Accelerated Phase Myeloproliferative Neoplasm (AP MPN) or Blast Phase Myeloproliferative Neoplasm

NCT05612633 is registered in ClinicalTrials.gov with Samus Therapeutics, Inc. as lead sponsor.

NCT NCT05612633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05612633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study of Zelavespib (PU-H71) in Subjects With Accelerated Phase Myeloproliferative Neoplasm (AP MPN) or Blast Phase Myeloproliferative Neoplasm
Lead sponsor
Samus Therapeutics, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
June 15, 2022
Completion date
February 23, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase mpn, blast phase mpn